GTCM
RIGL icon

Gyon Technologies Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Gyon Technologies Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-26,433
Closed -$1.15M – 471
2021
Q2 		$1.15M Buy
+26,433
New +$998K 0.38% 92
2021
Q1 		– Sell
-7,129
Closed -$249K – 495
2020
Q4 		$249K Buy
+7,129
New +$206K 0.09% 278

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gyon Technologies Capital Management's RIGL Position: Q3 2021 in Review

Gyon Technologies Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2021, closing a stake of 26,433 shares — an estimated $1.15M sold.

Gyon Technologies Capital Management first reported a position in RIGL in Q4 2020 and held it in 2 quarters. The position peaked at $1.15M in Q2 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q3 2021.

  • Gyon Technologies Capital Management reported no remaining Rigel Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 26,433 Rigel Pharmaceuticals shares in Q3 2021, an estimated $1.15M.
  • Gyon Technologies Capital Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Rigel Pharmaceuticals position peaked at $1.15M in Q2 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2021.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.